SCHEMBL5756834

SCHEMBL5756834

Cc1ccc(C(=O)NCc2ccc(Cl)cc2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.78
CCR1 P32246 7/20 0.62
HPGD P15428 2/20 0.53
LMNA P02545 1/20 0.53
ALDH1A1 P00352 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PLA2G1B P04054 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758770 0.92 ELANE (0.80) ELANECCR1ALDH1A1MEN1KMT2A
SCHEMBL5761301 0.91 ELANE (0.70) ELANECCR1HPGDLMNAMEN1
SCHEMBL5757209 0.91 ELANE (0.79) ELANECCR1HPGDLMNAALDH1A1
SCHEMBL5756606 0.91 ELANE (0.79) ELANECCR1HPGDLMNAALDH1A1
SCHEMBL5755788 0.91 ELANE (0.79) ELANECCR1HPGDLMNAALDH1A1
SCHEMBL5760251 0.90 ELANE (0.64) ELANECCR1HPGDLMNAMEN1
SCHEMBL5759071 0.90 ELANE (0.72) ELANECCR1HPGDLMNAMEN1
SCHEMBL5759291 0.90 ELANE (0.78) ELANECCR1HPGDLMNAALDH1A1
SCHEMBL5756979 0.90 ELANE (0.78) ELANECCR1HPGDLMNAALDH1A1
SCHEMBL5756974 0.90 ELANE (0.62) ELANECCR1HPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885CCR1 186/4885HPGD 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.